Collaboration with ANRT

Sep 10, 2015PRESS RELEASESHit 1776

MedPacto Inc. and ANRT have entered into a collaboration agreement for the development of novel biologics and monoclonal antibodies to develop drugs and diagnosis. The collaboration will focus on  the discovery and development of first-in-class therapies and diagnosis tools. Under the terms of the agreement, MedPacto, Inc. will share the outcome from the collaboration with ANRT

Next Announcement: 3rd annual general meeting of stockholders
Previous Phase I clinical trial dose escalation - 4th cohort